BAX - Baxter International Inc.
Both AbbVie (NYSE:ABBV | ABBV Price Prediction) and Baxter International (NYSE:BAX) flashed the same technical signal this month: a golden cross, where the 50-day moving average pushed above the 200-day.
DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a leading global medtech company, will host a conference call to discuss its second-quarter 2026 financial results on Thursday, July 30, 2026, at 7:30 a.m. Central Time. To participate in this conference call please follow this link https://events.q4inc.com/attendee/167756971 to pre-register for the call and receive the call information. This call is also being webcast and can be accessed through Baxter's website at www.bax.
Baxter International Inc. (NYSE: BAX), a global medtech leader, today published its newly renamed [url="]2025 Sustainability Report[/url], highlighting the comp
DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a global medtech leader, today published its newly renamed 2025 Sustainability Report, highlighting the company's progress and refreshed approach to advancing a sustainable and responsible business model. “As we shape Baxter's next chapter, our focus remains clear: making a meaningful difference for patients, customers and communities while working to create long‑term value for all stakeholders,” said Andrew Hider, presiden.
BAX gains as Synovis MCA signs a multi-year deal to commercialize MediThinQ's SHIYA 3D surgical visualization platform worldwide.
BAX is pursuing a broad turnaround as innovation, resilient demand, and AI integration support recovery despite regulatory risks and margin pressure.
Baxter International Inc. (BAX) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Baxter International Inc. (BAX) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Baxter International NYSE: BAX held its 2026 annual meeting of stockholders by webcast, with shareholders giving preliminary approval to all five proposals presented by the company, including the election of nine directors, executive compensation, auditor ratification, an amended incentive plan and a change related to board size.
In recent years, stocks like Baxter International have underperformed: most low-growth, high-debt, struggling names have been bad investments at basically any price. Concerns are real, and early missteps under new CEO Andrew Hider haven't helped. But valuation is attractive not just on an absolute basis but also relative to the outlook, and Q1 results seemed helpful to the bull case.
ICU Medical's new high-volume pump has more connected features, which we believe will drive retention rates and incremental revenue. SiteOne Landscape Supply controls 18% of this $26 billion industry and has been growing revenue at a low double-digit compound annual growth rate over the past several years. Madison Small Cap Fund liquidated its position in Globus Medical after a multi-year period because the company's success drove its market cap to $12B.
Baxter International Inc. (BAX) Q1 2026 Earnings Call Transcript
Baxter beats Q1 earnings and revenue estimates, sending shares higher despite declining profits and margin contraction.
The headline numbers for Baxter (BAX) give insight into how the company performed in the quarter ended March 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Baxter International (BAX) came out with quarterly earnings of $0.36 per share, beating the Zacks Consensus Estimate of $0.31 per share. This compares to earnings of $0.55 per share a year ago.
Baxter on Thursday beat Wall Street estimates for first-quarter profit and revenue, helped by robust sales in its medical products and therapies unit.
On April 30, 2026, Baxter International Inc (BAX) released its 8-K filing detailing first-quarter 2026 results. Sales from continuing operations were $2.7 billi
DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE: BAX), a global medtech leader, today reported results for the first quarter of 2026. “Financial results for the quarter overall were in line with our expectations, and we are making progress to stabilize the business, embed a culture of continuous improvement, and strengthen execution,” said Andrew Hider, president and CEO. “Although more work remains to achieve our full potential, Baxter continues to take the decisive steps nec.
QuidelOrtho (QDEL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
BAX heads into Q1 earnings with revenues and profit set to fall sharply as operational pressures, weak demand and product disruptions weigh on results.